Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults
Dermatologic Therapy2020Vol. 33(3), pp. e13290–e13290
Citations Over TimeTop 12% of 2020 papers
Cataldo Patruno, Luca Stingeni, Katharina Hansel, Silvia Mariel Ferrucci, Simona Tavecchio, Gabriella Fabbrocini, Steven Paul Nisticò, Caterina Foti, Serena De Prezzo, Maddalena Napolitano
Abstract
Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.
Related Papers
- → Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults(2020)22 cited
- → Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients(2024)8 cited
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.(2021)
- → 27431 Dupilumab treatment improves health-related quality of life in children aged ≥6 to <12 years with severe atopic dermatitis(2021)1 cited